AUSTIN,
Texas, May 5, 2022 /PRNewswire/
-- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a
multi-national epigenetics company plans to host a Capital Markets
Day in a hybrid format on Friday, May 13, 2022, at
10 a.m. U.S. Eastern Time.
Volition's executive team will provide strategic updates and
discuss the Company's key short-term growth drivers.
Event: VolitionRx Limited Capital Markets Day
Date: Friday, May 13, 2022
Time: 10:00 a.m. Eastern
time
In-person Venue: Siebert
Hall, New York Stock Exchange
To attend in person, contact investorrelations@volition.com
To attend
virtually please register HERE
Company presentations will cover:
Nu.Q® Vet
- Veterinary market opportunity (reference lab and point of
care)
- Heska licensing deal (up to $28
million in milestone payments PLUS ongoing revenue for tests
sold)
- Other licensing updates
- New Product updates
Nu.Q® NETs
- Clinical Results to-date
- Clinical and Regulatory plan including FDA timings
- Market opportunity
- Financial Update: Key Metrics and Considerations
A question-and-answer session with management will follow the
prepared remarks and formal presentation.
To attend the event in-person please contact
investorrelations@volition.com
To access the virtual event, register by clicking
HERE.
The event will be webcast and the presentations will be posted
to Volition's website. A replay will be made available.
For additional information or questions please contact Investor
Relations at investorrelation@volition.com or call 646 650 1351
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's Nu.Q® technology go to:
www.volition.com
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients but also improve their quality of
life. The tests are based on the science of Nucleosomics™, which is
the practice of identifying and measuring nucleosomes in the
bloodstream or other bodily fluid - an indication that disease is
present. Volition is primarily focused on human diagnostics and
monitoring but also has a subsidiary focused on animal diagnostics
and monitoring.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory in California and
additional offices in Texas,
London, and Singapore, as the company focuses on bringing
its diagnostic and disease monitoring products to market.
For more information about Volition, visit Volition's website or
connect with us via Twitter, LinkedIn, and Facebook.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Investor Enquiries:
Scott Powell, Volition,
investorrelations@volition.com +1 (646) 650 1351
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-to-host-capital-markets-day-on-friday-may-13-301540753.html
SOURCE VolitionRx Limited